Aqua-Therapeutics Co. receives capital injection for nucleic acid-therapy, directed at diabetic retinopathy

Aqua-Therapeutics Co., a startup company in Fukuoka, has received 450 million Yen capital investment through a public-private partnership for accelerated development of its nucleic-acid based drug development for the treatment of diabetic retinotherapy. Other targets are viral infections and tumor treatment

Aqua-Therapeutics press release, April 1, 2013

Most popular posts: